Новости | Магазин | Журналы | Контакты | Правила | Доставка | |
Вход Регистрация |
В статье описаны аберрации гена MYC в зависимости от клиникоморфологических факторов при протоковой аденокарциноме поджелудочной железы. Показана связь между обнаруженными аберрациями гена MYC и выживаемостью больных при раке поджелудочной железы
Ключевые слова:
протоковая аденокарцинома поджелудочной железы, FISH-анализ, ген MYC, аберрация
Литература:
1. Hamilton R., Lauri A. Aaltonen. Tumours of the digestive system.
Lyon: WHO, 2010.
2. Alberts B., Johnosn A., Lewis J. el. al. Molecular biology of the
cell. 5th ed. New York: Garland Science, 2002.
3. Duensing S., Darr S., Cuevas R. et. al. Tripeptidyl Peptidase II Is
Required for cMYCInduced Centriole Overduplication and
a Novel Therapeutic Target in cMYCAssociated Neoplasms //
Genes Cancer. 2010. V. 1. N 9. P. 883–892.
4. Leal M.F., Calcagno D.Q., Borges da Costa J.F. et. al. MYC,
TP53, and chromosome 17 copynumber alterations in multiple
gastric cancer cell lines and in their parental primary tumors.
Tripeptidyl Peptidase II Is Required for c-MYC-Induced
Centriole Overduplication and a Novel Therapeutic Target in
cMYCAssociated Neoplasms // J. Biomed. Biotechnol. 2011.
Published online 2011: Feb. 23. 631268.
5. Schwab M., Amler L.C. //Amplification of cellular oncogenes:
a predictor of the clinical outcome in human cancer //Gen.
Chromos. Cancer. 1990. V. 1. P. 181–193.
6. Koskinen P.J., Alitalo K. Role of myc amplification and overexpression in cell growth, differentiation and death // Semin.
Cancer. Biol. 1993. V. 4. P. 3–12.
7. Nesbit C.E., Tersak J.M., Prochownik E.V. MYC oncogenes and
human neoplastic disease // Oncogene. 1999. V. 18. P. 3004–3016.
8. Кабилова Т.О., Черноловская Е.Л. Онкогены семейства MYC
как терапевтические мишени // Бюл. Cиб. мед. 2008. Приложение 3. С. 11–26.
9. Schleger Ph.D., C Verbeke M.D., R Hildenbrand M.D. et al.
cMYC Activation in Primary and Metastatic Ductal Adenocarcinoma of the Pancreas: Incidence, Mechanisms, and
Clinical Significance // Cur. Probl. Cancer. 2002.2002. V. 15.
N 4. P. 462–469.
10. Felsher D.W., Bishop J.M. Reversible tumorigenesisi by MYC in
hematopoietic lineages // Mol. Cell. 1999. V. 4. P. 199–207.
11. D’Cruz C.M., Gunther E.J., Boxer R.B. et al. CMYC induces
mammary tumorigenesis by means of a preffered pathway involving spontaneous Kras2 mutations // Nat. Med. 2001. V. 7.
P. 235–239.
12. Shachaf C.M., Kopelman A.M., Arvanitis C. et al. MYC inactivation uncovers pluripotent differentiation and tumor dormancy in
hepatocellular cancer // Nature. 2004. V. 431. P. 1112–1117.
13. Arnold I., Watt F.M. CMYC activation in transgenic mouse epidermis results in mobilization of stem cells and differentiation of
their progeny // Cur. Biol. 2001. V. 11. P. 558–568.
14. Pelengaris S., Khan M., Evan G.I. Supression of MYC-induced
apoptosis in beta cells exposes multipl oncogenic properties of
MYC and triggers carcinogenic progression // Cell. 2002. V. 109.
P. 321–334.
15. Реброва О.Ю. Статистический анализ медицинских данных. М.: Медиа Сфера, 2002.
16. Hirai I., Kimura W., Orawa K. et. al. Perinevral invasion in pancreatic cancer // Pancreas. 2002. V. 4. N 1. P. 15–25.
17. Takahashi T., Ishhikura H., Motohara T. et al. Perineural invasion by ductal adenocarcinoma of the pancreas // J. Surg. Oncol.
1997. V. 65. P. 164–170.
MYC gene amplifications in accordance of clinicalmorphological factors of a pancreatic ductal cancer are describeв in the article. A connection of the MYC gene amplifications expression and the survival prognosis of pancreatic ductal cancer patients is presented
Keywords:
pancreatic ductal cancer, Fish-analysis, MYC gene, amplification.